An early clinical trial in individuals with the deadly brain cancer, glioblastoma, showed an experimental spherical nucleic acid drug developed by Northwestern University scientists was able to penetrate the blood-brain barrier and trigger the death of tumor cells. Lead investigator, Priya Kumthekar, MD, explains the results of the study.
